Fierce Pharma13h
Novartis snags FDA nod for Fabhalta in another kidney disease but leaves room for rival Apellis
Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...
Neurology Advisor13h
FDA Fast Tracks Investigational Nonopioid Treatment for Acute Pain
The Food and Drug Administration has granted Fast Track designation to LTG-001 for the treatment of acute pain.
Health Affairs15h
Fosamax Lawsuit: The Importance Of State Duties To Warn Of Drug Dangers
Fosamax further defines the obligation of drug manufacturers to present clear, unambiguous, and accurate information to the ...